MAIA MAIA Biotechnology, Inc.

AMEX
$1.40

MAIA Biotechnology, Inc. (MAIA) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.12 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.5% since its last earnings release on August 10, 2026.

MAIA Biotechnology Missed Consensus Estimates
Monday, August 10, 2026 · 12:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · After Close
Earnings Whisper
-
vs ($0.12)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.39

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About MAIA Biotechnology, Inc.

MAIA Biotechnology Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of patients with telomerase-positive cancers. MAIA Biotechnology Inc. is based in CHICAGO.

Sector

Healthcare

Industry

Biotechnology